drugset / Trial / NCT05381207

Impact Of Montelukast On Allergic Rhinitis And Its Inflammatory Makers

NCT05381207

Phase 0 Unknown 60 enrolled Assiut University
RandomizedParallel-groupSingle-blindTreatment

Summary

To examine the efficacy of Montelukast as an adjunct to INCS in patients with allergic rhinitis.

Timeline

Start
2022-10
Primary completion
2024-10
Completion
2024-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Montelukast Other / unclassified 10 mg Oral
Comparator Fluticasone Furoate Other / unclassified 100 ug Intranasal

Indications